Journal article
Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis
AD Cook, AL Turner, EL Braine, J Pobjoy, JC Lenzo, JA Hamilton
Arthritis and Rheumatism | WILEY-BLACKWELL | Published : 2011
DOI: 10.1002/art.30354
Abstract
Objective Even though there are clinical trials assessing granulocyte-macrophage colony-stimulating factor (GM-CSF) blockade in rheumatoid arthritis (RA), questions remain as to how GM-CSF acts as a proinflammatory cytokine. The aims of this study on the regulation of arthritis progression by GM-CSF were to determine the source of the GM-CSF, whether there are systemic effects, the changes in synovial tissue leukocyte populations, and the arthritis model dependence on GM-CSF. Methods Bone marrow chimeras were used to determine the source of GM-CSF required for the development of collagen-induced arthritis (CIA). The K/BxN serum-transfer model of arthritis was tested in GM-CSF -/- mice and us..
View full abstractGrants
Funding Acknowledgements
Supported by the National Health and Medical Research Council of Australia. Professor Hamilton is recipient of a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia.Professor Hamilton has received consulting fees from MorphoSys AG and CSL, Ltd. (less than $10,000 a year). The University of Melbourne has licensed to MorphoSys AG, Germany, patented technology relating to therapeutically targeting granulocyte-macrophage colony-stimulating factor, for which licensing fees and milestone payments have been made.